CorMedix Inc. (CRMD) Starts Presentation at B. Riley Conference
CorMedix (NYSE: CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections, currently in phase 3 development. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provide the potential for priority review of a marketing application by FDA. Neutrolin is already marketed as a CE Marked product in Europe and other territories. For more information, visit the company's…







